CPT.one Biotech is a Danish privately funded biotech company, dedicated to the development of novel treatments for patients suffering from multiple sclerosis (MS). We are primarily focusing on secondary progressive multiple sclerosis (SP-MS).
Our platform is built on CPT-001, which is an irreversible inhibitor of carnitine palmitoyltransferase-1 (CPT-1), and it is partly in-licensed and further developed by CPT.one Biotech. It has a first in class mode of action and block lipid transport in the mitochondria and thereby regulate fat and glucose metabolism. The target is mitochondrial CPT1 and the treatment reestablishes defectives in myelin sheets.
We are working with leading scientists on relevant indications and are open to working with partners to accelerate the development of new therapies based on our platform. CPT.one Biotech's pioneering science and licences to our intellectual property, are available to companies through discovery partnerships to develop novel therapies for patients with high unmet need, using our proprietary CPT1-based technology platform.
Talk to us about partnering.
CPT.one was founded by M.Sc. Jette Goller Kloth in collaboration with Aalborg University.